ATE480563T1 - Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper - Google Patents

Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper

Info

Publication number
ATE480563T1
ATE480563T1 AT06706900T AT06706900T ATE480563T1 AT E480563 T1 ATE480563 T1 AT E480563T1 AT 06706900 T AT06706900 T AT 06706900T AT 06706900 T AT06706900 T AT 06706900T AT E480563 T1 ATE480563 T1 AT E480563T1
Authority
AT
Austria
Prior art keywords
iats
serotype
human monoclonal
lipopolysaccharides
lps
Prior art date
Application number
AT06706900T
Other languages
German (de)
English (en)
Inventor
Alois Lang
Michael Horn
Martin Imboden
Adrian Zuercher
Original Assignee
Kenta Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech Ag filed Critical Kenta Biotech Ag
Application granted granted Critical
Publication of ATE480563T1 publication Critical patent/ATE480563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06706900T 2005-02-14 2006-02-13 Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper ATE480563T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (en) 2005-02-14 2005-02-14 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
PCT/EP2006/001289 WO2006084758A1 (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Publications (1)

Publication Number Publication Date
ATE480563T1 true ATE480563T1 (de) 2010-09-15

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06706900T ATE480563T1 (de) 2005-02-14 2006-02-13 Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper

Country Status (11)

Country Link
US (1) US8197816B2 (https=)
EP (2) EP1690875A1 (https=)
JP (1) JP4944799B2 (https=)
KR (2) KR20070107756A (https=)
CN (1) CN101120018B (https=)
AT (1) ATE480563T1 (https=)
CA (1) CA2597701C (https=)
DE (1) DE602006016736D1 (https=)
ES (1) ES2348263T3 (https=)
IL (1) IL184774A (https=)
WO (1) WO2006084758A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571673A1 (en) * 2004-06-28 2006-01-05 Proteome Systems Intellectual Property Pty Ltd Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor
EP2417157A1 (en) * 2009-04-09 2012-02-15 Kenta Biotech AG Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa
KR20120128686A (ko) * 2010-02-18 2012-11-27 심포젠 에이/에스 녹농균의 혈청형 ａ 지질다당류에 대한 항체
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits
CA2925897A1 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
JP4398620B2 (ja) 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
EP1319025A2 (en) * 2000-09-07 2003-06-18 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse

Also Published As

Publication number Publication date
EP1690875A1 (en) 2006-08-16
JP2008530988A (ja) 2008-08-14
DE602006016736D1 (de) 2010-10-21
KR20070107756A (ko) 2007-11-07
IL184774A0 (en) 2007-12-03
EP1848741A1 (en) 2007-10-31
US20090068191A1 (en) 2009-03-12
EP1848741B1 (en) 2010-09-08
ES2348263T3 (es) 2010-12-02
KR20130018991A (ko) 2013-02-25
JP4944799B2 (ja) 2012-06-06
CA2597701A1 (en) 2006-08-17
CN101120018B (zh) 2012-07-25
CN101120018A (zh) 2008-02-06
IL184774A (en) 2012-01-31
US8197816B2 (en) 2012-06-12
CA2597701C (en) 2012-01-10
WO2006084758A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
IL184774A0 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
NO20074563L (no) Novel anti-plgf antibody
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA200802168A1 (ru) Гуманизированное антитело к с-kit
WO2010009987A3 (en) Diagnostic antibody assay
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
EP1938155A4 (en) BUSINESS PROCESS EXECUTE ENGINE
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
ATE458006T1 (de) Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
DE602006015929D1 (de) Doxorubicin-immuntest
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE494552T1 (de) Docetaxel-immuntest

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1848741

Country of ref document: EP